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Purpose: Since the publication of Dialysis Outcomes Quality Initiative (DOQI) guidelines, the use of native veins for the
construction of arteriovenous fistulas (AVF) for hemodialysis has been highly recommended rather than prosthetic
arteriovenous grafts (AVG). Upper arm basilic vein transposition (BVT) has been accepted widely, with superior patency
compared with AVG, but only a few studies have reported outcomes of forearm BVT (FBVT). This study evaluated the
efficacy of FBVT compared with direct AVF (DAVF) and AVG in a tertiary referral center.
Methods: From January 2005 to December 2007, 461 patients underwent AV access for hemodialysis in Seoul National
University Hospital. We retrospectively reviewed the medical records and dialysis sheets and evaluated the current AVF
function in the outpatient clinic or by telephone interviews. Patients were grouped by the operation type: DAVF, FBVT,
and AVG. The outcomes compared were primary, assisted-primary and secondary patency rates, maturation failure, and
complications.
Result: The mean age was 59 years (range, 14-92 years), and 280 patients (60.7%) were male. By operation type, the 461
accesses were 389 DAVF (84.4%), 34 FBVT (7.4%), and 38 AVG (8.2%). Mean follow-up duration was 21 months
(range, 1-51 months). The primary patency rates for DAVF, FBVT, and AVG were 67.6%, 41.5%, 35% at 12 months and
53.9%, 30.2%, 10.3% at 24months, respectively. The secondary patency rates were 89.2%, 79.1%, 78.3% at 12months and
83.8%, 74.4%, 64.9% at 24 months, respectively. Maturation failure occurred in five DAVF patients and in one FBVT
patient. The infection rate was 0.3% in DAVF and 12.5% in AVG, but no infection occurred in patients with FBVT.
Multivariate analysis revealed that age and history of previous access were associated with lower primary patency.
Conclusion: Forearm BVT showed an acceptable, high 2-year patency rate and fewer thromboses and infectious
complications than AVG. Forearm BVT could be considered before forming an upper arm AVF or forearm AVG, if the
basilic vein is available. ( J Vasc Surg 2010;51:667-72.)It is essential to secure and maintain vascular access for
proper dialysis in patients receiving maintenance hemodi-
alysis. The ideal vascular access should be durable, have
minimal risk of infection, and require few interventions to
maintain patency. The National Kidney Foundation Dialy-
sis Outcome Quality Initiative (NKF K/DOQI) guidelines
published in 1997 encouraged the use of autogenous arte-
riovenous fistulas (AVFs), emphasizing that they could
maintain long life spans with minimal complications and
interventions.1 According to the guideline, autogenous
AVFs have been preferred over prosthetic arteriovenous
grafts (AVGs).
The formation of an AVF through upper arm basilic
vein transposition (UBVT) is another method of using
autogenous vessels and has been attempted by many
groups.2-9 Although this method has some disadvantages,
including technical difficulty, longer operation times, and
longer maturation duration, it is widely accepted because of
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Few studies have been done on the patency rates of
forearm BVT (FBVT).10-12 We thought that forearm ba-
silic vein could be used as an alternative for UBVT, provid-
ing another option for autogenous hemodialysis access. It
could be used in patients with failed direct AVFs (DAVFs),
such as radial-cephalic direct wrist access or brachial-
cephalic upper arm direct access. With the initial successes
performing FBVT in our hospital, we hypothesized that
FBVT could be done safely with an acceptable long-term
patency and few complications. The purpose of this study
was to evaluate the efficacy of FBVT compared with DAVF
and AVG in a single tertiary referral center.
METHODS
From January 2005 through December 2007, 461
patients underwent AV access for hemodialysis in Seoul
National University Hospital. The medical records and
dialysis records were retrospectively reviewed, and current
AVF function was evaluated in the outpatient clinic or by
telephone interviews. Patients were grouped by the opera-
tion type: DAVF, FBVT, or AVG. The DAVF group in-
cluded autogenous radial-cephalic and brachial-cephalic
AVFs, and AVG included forearm straight or loop grafts.
For the FBVT, careful physical examinations and du-
plex ultrasound (DUS) imaging were conducted to deter-
mine whether a forearm basilic vein could be used, with the
criteria being a basilic vein diameter 2.5 mm throughout
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the DAVF, the same preoperative evaluation and criteria
were applied to the cephalic vein.
For the transposition of the forearm basilic vein, three
or four separate skin incisions were made under local anes-
thesia from the antecubital fossa to the wrist, and the basilic
vein was dissected free. The radial artery at the wrist was
exposed. The basilic vein was transposed through a subcu-
taneous tunnel on the volar aspects of the forearm, and an
end-to-side anastomosis was performed with the radial
artery (Fig 1). The vein was marked before it was passed
through the tunnel to prevent kinking or twisting.
The outcomes of function and patency were evaluated,
including primary, assisted primary, and secondary patency
rates, maturation failure, and complications. Maturation
failure was defined as early occlusion or unsuitable for
hemodialysis 8 weeks after the AV access creation. The
Fig 1. A, Operative field is shown after dissection of the forearm
basilic vein. Separate skin incisions were made along the basilic vein
from wrist to elbow. The basilic vein was transposed to the volar
side of the forearm through a subcutaneous tunnel. An end-to-side
anastomosis was made with the radial artery at the wrist.
B, Operative field is shown after closure.primary, assisted-primary, and secondary patency rates weredefined according to the Society for Vascular Surgery
guideline.3
The data are expressed as mean standard deviation.
Patient characteristics were compared by the Mann-
Whitney and 2 tests. Patency rates were evaluated using
Kaplan-Meier plots and compared using log-rank analysis.
A value of P  .05 was considered statistically significant.
Statistical analysis was performed using SPSS 12.0 software
(SPSS Inc, Chicago, Ill).
RESULTS
Patient demographics. The mean age was 59  15.1
years, and there were 280 men (60.7%) and 181 women
(39.2%). The 461 cases included 389 DAVFs (84.4%), 34
FBVTs (7.3%), and 38 AVGs (8.2%). Direct AVFs included
300 radial-cephalic AVFs and 89 brachial-cephalic AVFs.
The follow-up period was 21.6  12.6 months (range,
1-51 months). The patients in the DAVF group were
significantly younger (58.5 14.9 vs 66.7 12.5 years, P
.001), had fewer cardiovascular or cerebrovascular diseases,
and had undergone fewer previous vascular accesses for
dialysis than the patients in the AVG group (Table I).
Diabetes and hypertension were the most frequent cause of
renal failure in all groups.
Patency rates. The average primary patency periods
were 29.4 1.2 months in the DAVF group, 16.9 2.9 in
the FBVT group, and 12.6  1.9 in the AVG group. The
DAVF group showed better patency than the FBVT or
AVG groups (P  .005). The difference between the
primary patencies of the FBVT and AVG groups was not
statistically significant (P .238), although the period was
longer in the FBVT group. The 12-month primary patency
rates of DAVFs, FBVTs, and AVGs were 67.6%, 41.5%, and
35.0%, respectively (Fig 2). The 24-month primary patency
rates were 53.9%, 30.2 %, and 10.3%, respectively. The
primary-assisted patency rates were 88.6%, 79.1%, and
75.6% at 12 months and 82.5%, 74.4%, and 65.5% at 24
months (Fig 3). The secondary patency rates were 89.2%,
79.1%, and 78.3%, respectively, at 12 months and 83.8%,
74.4%, and 64.9% at 24 months (Fig 4).
The direct AVF group included 300 radial-cephalic
AVFs (RC-AVFs) and 89 brachial-cephalic AVFs (BC-
AVFs). The patencies in each subgroup were compared
with FBVT. The primary, assisted-primary, and secondary
patency periods of the BC-AVF subgroup were 30.4 2.5,
44.2  1.9 and 44.3  1.9, respectively. The primary,
assisted-primary, and secondary patency periods of the
RC-AVF subgroup were 28.0  1.3, 41.3  1.1, and
47.8  1.7, respectively. The differences in the patency
rates between BC-AVF and RC-AVF patients were not
statistically significant. In comparison with the FBVT sub-
group, the BC-AVF and RC-AVF subgroups both showed
better primary patency (P  .01), although primary-
assisted and secondary patencies were not different.
Risk factors such as age, gender, diabetes, hyperten-
sion, cerebrovascular disease, previous access history, and
access type were analyzed with logistic regression. Primary
patency rates were significantly lower in patients aged 60
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patients with access other than a DAVF (Table II).
Maturation failure and other complications.
Maturation failure until 8 weeks postoperatively developed
in 15 patients: 10 AVF patients (2.5%) and in five BVT
Table I. Patient demographics and clinical data
Characteristic DAVF
Type of access, No. (%) 389 (84.4)
Age, y
Mean  SD 58.54  15.35a
Range 14-92
Gender, No. (%)
Male 232 (59.6)
Female 157 (40.4)
Follow-up interval, mon
Mean  SD 15.39  9.46
Range 1-40.8
Comorbidities, No. (%)
Diabetes 193 (49.6)
Hypertension 321 (82.7)
CAD 72 (18.6)a
CVD 34 (8.8)a
Etiology of renal failure
Diabetes 184 (47.3)
Hypertension 37 (9.5)
IgA nephropathy 21 (5.4)
Unknown 59 (15.2)
Others 88 (22.6)
AVG, Arteriovenous graft (prosthetic);CAD, coronary artery disease;CVD,
vein transposition; IgA, immunoglobulin A; SD, standard deviation.
aThe P value is the result of comparison between the marked groups.
Fig 2. Kaplan-Meier curves show primary patency rates for direct
arteriovenous fistulas (DAVFs), forearm basilic vein transpositions
(FBVTs), and prosthetic arteriovenous grafts (AVGs).patients (14.7%; Table III). Among them, new access op-erations were performed in four patients, three in the AVF
group, and one in the BVT group. Infection developed in
one AVF patient and in five AVG patients. Importantly,
there were no infectious complications in the BVT group.
Wound seroma or hematoma developed in one AVF and in
FBVT AVG P value
34 (7.4) 38 (8.2)
.29  11.84 66.87  12.44a .001
32-81 24-86
24 (70.6) 24 (63.2) NS
10 (29.4) 14 (36.8)
.42  10.99 16.65  7.38 NS
1.5-41.6 5.1-39.4
18 (52.9) 24 (63.2) NS
24 (70.6) 33 (86.8) NS
9 (30.0) 13 (34.2)a .022
3 (8.8) 13 (34.2)a .008
18 (52.9) 21 (55.3) NS
4 (11.8) 5 (13.2) NS
0 (0) 1 (2.6) NS
2 (5.9) 5 (13.2) NS
10 (29.4) 6 (15.7) NS
rovascular disease;DAVF, direct arteriovenous fistula; FBVT, forearm basilic
Fig 3. Kaplan-Meier curves show primary-assisted patency rates
for direct arteriovenous fistulas (DAVFs), forearm basilic vein
transpositions (FBVTs), and prosthetic arteriovenous grafts
(AVGs).62
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cerebone BVT patient, which were treated by minor drainage
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significantly higher maturation failure rate of 14.7% vs 2.5%
(P  .004). Compared with AVGs, FBVTs showed signif-
icantly fewer thrombosis and infection (P  .001).
DISCUSSION
Thanks to the development of medical technology, the
mean age of patients depending on dialysis has increased,
and the lifespan of patients with renal failure has also
increased, making the preservation of vessels for vascular
access more important. Although direct autogenous AVFs
on the wrist or the antecubital fossa are the most preferred,
sometimes vascular conditions are not suitable due to dam-
age caused by frequent injections, previous vascular access
operations, or old age. The AVF made through venous
transposition has been regarded as another way to use
autogenous vessels following the NKF-DOQI recommen-
dation1 that actively encouraged the use of autogenous
vessels. The use of upper arm BVT (UBVT) was first
published by Dagher et al2 in 1976. This AVF has the
advantage of a higher patency rate than that of prosthetic
grafts and a lower infection rate.5-7 However, the disadvan-
tages include longer operation time, longer maturation
period required, possible vein damage during dissection,
and frequent wound problems owing to the longer inci-
sion. The 1-year primary patency rates of the UBVT are
reported as 23% to 90%, whereas 1-year secondary patency
rates are 47% to 96%.3-9 On the basis of these reports,
UBVT is now widely accepted for a permanent hemodial-
ysis access.4-9 However, there are few reports on the pa-
tency rate of forearm BVT (FBVT).10-12 Although only 10
Fig 4. Kaplan-Meier curves show of secondary patency rates for
direct arteriovenous fistulas (DAVFs), forearm basilic vein trans-
positions (FBVTs), and prosthetic arteriovenous grafts (AVGs).cases were included in a retrospective study, Gormus et al10reported a 90% patency rate for FBVT at 10 months and
80% for UBVT. Weyde et al11 reported patency rates of
FBVT as 70.4% at 1 year and 48.4% at 3 years.
The 12- and 24-month primary patency rates of the
FBVTs in our series were 41.5% and 30.2%, which were
relatively low. However, the primary-assisted patency rates
were 79.1% and 74.4%, and the secondary patency rates
were 79.1% and 74.4%, respectively. The low primary pa-
tency rates could be interpreted as the consequence of our
hospital policy to perform active surveillance and early
intervention. Our periodic surveillance program uses du-
plex ultrasound imaging when the arterial flow is 300
mL/min during dialysis, and balloon angioplasty is per-
formed when there is any stenosis.
One FBVT thrombosed during the follow-up period.
The patient had diffuse stenosis of the AVF, and a new
brachial-cephalic AVF was created on the upper arm. This
can explain the same primary-assisted patency and second-
ary patency rates. The patency rates of direct AVFs are
better than those of FBVTs or AVGs. The overall patency
rate of FBVTs was statistically similar to that of AVGs,
although the patency period was longer in FBVTs. We
suspect that this can be a type II statistical error because of
the small sample size, which should be proved in further
studies. Complications such as thrombosis and infection
were significantly less frequent in patients with BVTs than
in those with AVGs.
The maturation failure rate of the FBVT is 14.7%,
which is higher than that of the DAVF (2.5%). However,
most are salvageable by percutaneous intervention, and
only one patient needed reoperation. Others have reported
reoperation rates of 20% to 40% before the first use of an
AVF,13-15 and 6% to 23% for UBVTs.16-18
Meanwhile, forearm or upper arm BVT is believed to
be subject to many technical complications, such as wound
complications, due to the long incision and vein kinking or
twisting during tunneling. We can, however, minimize
those problems with meticulous surgical technique, as de-
scribed above.
We had no patient with a UBVT during the study
period. In cases unsuitable for direct a AVF or FBVT, we
asked the patient to choose the access type between the two
options of UBVT or forearm AVG. Because of the deep
location of the upper arm basilic vein, we usually performed
the UBVT under general anesthesia, to which most of the
patients were reluctant.
On the basis of these results, we perform FBVT prefer-
entially when a radial-cephalic AVF fails or when a forearm
cephalic vein is not suitable. Fistulas using brachial artery
inflow, such as a brachial-cephalic AVF or a forearm loop
graft, can be reserved for future use. The rationales for
performing an FBVT before an AVG can be summarized as
follows: First, the patency rate of the FBVT is comparable
with that of an AVG. Second, infectious complication is far
less in a BVT. Third, even if the FBVT does not increase in
size enough to be used for dialysis, it may contribute to a
larger upper arm basilic vein, which then could be used for
long-term dialysis. And finally, when FBVT fails, a forearm
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possible. The remaining concern about the FBVT is the
high maturation failure rate. We think this can be reduced
with careful patient selection. Early intervention of the
stenotic segment can achieve maturation, as in our series.
To increase the use of the FBVT, careful examination
for the presence of a forearm basilic vein by a vascular
surgeon is very important. Frequently, uninjured forearm
basilic vein could be found and offered a good conduit for
long-term hemodialysis.
CONCLUSION
This study shows that the forearm basilic vein transpo-
sition has an acceptable, high 2-year patency rate and fewer
complications than expected. For patients with a failed
wrist radial-cephalic AVF or no suitable forearm cephalic
vein, the presence of a forearm basilic vein should be
examined. Formation of a forearm basilic vein transposition
AVF could be considered before forming an upper arm
AVF or a forearm prosthetic graft.
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Table II. Multivariate analysis of factors associated with th
Covariate
Primary patency
aRR (95% CI)
Old age 1.015 (1.004-1.026)
Female sex 1.102 (0.827-1.467)
Diabetes 0.912 (0.685-1.213)
Hypertension 0.891 (0.615-1.291)
CVD 1.073 (0.682-1.688)
Previous access 1.514 (1.110-2.065)
Access type
DAVF 1
FBVT 1.667 (1.045-2.660)
AVG 2.165 (1.417-3.308)
aRR, Adjusted relative risk; AVG, prosthetic arteriovenous graft; CI, confid
FBVT, forearm basilic vein transposition.
Table III. Complications during the follow-up
Complicationa DAVF FBVT AVG P value
Maturation failure 10 (2.5)a 5 (14.7)a 0 .004
Thrombosis 11 (2.8) 1 (2.9)a 10 (26.3)a .001
Seroma/hematoma 1 (0.03) 1 (2.9) 0 NS
Infection 1 (0.03) 0a 5 (13.2)a .001
Steal syndrome 1 (0.03) 0 0 NS
AVG, prosthetic arteriovenous graft; DAVF, direct arteriovenous fistula;
FBVT, forearm basilic vein transposition; NS, not significant.
aThe P value is the result of comparison between the marked groups.Statistical analysis: HS, SKM, YPObtained funding: Not applicable
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